Evidence map›Paper›PMID 25623409›Full record

Trial reportAlcoholism, clinical and experimental research2015

Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.

Matthew J Worley, Katie Witkiewitz, Sandra A Brown, Daniel R Kivlahan, Richard Longabaugh

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Alcoholism, clinical and experimental research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Trial
  5. Trial
  6. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015
    Trial
  7. Trial
  8. Review
  9. Distress tolerance trajectories following substance use treatment.Journal of consulting and clinical psychology · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Matthew J WorleyDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, California.
Katie Witkiewitz
Sandra A Brown
Daniel R Kivlahan
Richard Longabaugh
Brown University · USUniversity of California, Los Angeles · USUniversity of California San Diego · USUniversity of New Mexico · USUniversity of Washington · US

Funding

Precision Medicine and Recovery in a Telehealth Treatment Program for Alcohol Use DisorderR01AA022328 · NIAAA · UNIVERSITY OF NEW MEXICO · PI Katie A Witkiewitz · 2013 to 2026
$3.1M
Mediators of Outpatient Treatment for Comorbid Substance Use Disorder and Major DF31DA030861 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WORLEY, MATTHEW J. · 2011 to 2012
$66k
NIAAA NIH HHS R01 AA022328NIDA NIH HHS F31 DA030861
6 · The paper itself

Abstract

backgroundOral naltrexone is an efficacious medication for treatment of alcohol dependence, but small effect sizes and variability in outcomes suggest the presence of person-level moderators of naltrexone response. Identification of contextual or psychosocial moderators may assist in guiding clinical recommendations. Given the established importance of social networks in drinking outcomes, as well as the potential effects of naltrexone in reducing cue reactivity which may be especially important among those with more heavy drinkers and more alcohol cues in their networks, we examined pretreatment social network variables as potential moderators of naltrexone treatment effects in the COMBINE study.

methodsThe sample included all COMBINE study participants in medication conditions with full data on the Important People Inventory (IPI) and covariates at intake (N = 1,197). The intake IPI assessed whether participants had any frequent drinkers in their network and the average frequency of contact with these drinkers. The effects of treatment condition, pretreatment network variables, and their interactions on percent heavy drinking days were tested in hierarchical linear models, controlling for demographics and baseline clinical covariates.

resultsIn treatment conditions involving medical management and combined behavioral intervention (CBI), the effects of active naltrexone on heavy drinking were significantly greater for individuals with frequent drinkers in their network (z = -2.66, p < 0.01) and greater frequency of contact with those drinkers (z = -3.19, p < 0.01). These network variables did not moderate the effects of active naltrexone without CBI.

conclusionsWhen delivered in conjunction with behavioral interventions, naltrexone can be more potent for alcohol-dependent adults who have greater contact with frequent drinkers prior to treatment, which may indicate patterns of environmental exposure to alcohol. Contextual, social risk factors are a potential avenue to guide personalized treatment of alcohol dependence.

Indexed as

Alcohol DrinkingBehavior TherapySocial SupportAdultAlcoholismCombined Modality TherapyCravingFemaleHumansMaleMiddle AgedNaltrexoneNarcotic AntagonistsTreatment OutcomeYoung AdultNaltrexoneNarcotic AntagonistsAlcohol DependenceModeratorsNaltrexonePharmacotherapySocial Network

Identifiers

PMID25623409
PMCPMC4418469
OpenAlexW2061431392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.